Mitsubishi Tanabe Pharma America (MT Pharma America) has enrolled more than 700 sites of care in its newly created National Infusion Center Directory to help physicians identify local infusion centers for amyotrophic lateral sclerosis (ALS) patients who are prescribed Radicava (edaravone).
Military veterans are twice as likely to develop amyotrophic lateral sclerosis (ALS) as those who haven’t served in the military. MORE: Explaining the progression of ALS Despite extensive research into the topic, scientists are still unable to find the link between serving in the military and developing ALS.  According to the…
https://www.youtube.com/watch?v=FvC5KheFWG8 This video from Patients Like Me is all about Cris, who is a mother, grandmother, and great-grandmother. Cris also has amyotrophic lateral sclerosis (ALS). She was diagnosed two years ago but hasn’t had the time to sit around and get depressed about her diagnosis. In between spending time with…
Researchers have slowed the progression of an ALS-like disease in mice, and prolonged their lives, by reducing the activity of a protein receptor that helps transmit signals between nerve cells. The study, which involved the metabotropic glutamate receptor 5, or mGluR5, was published in the journal Neuropharmacology. The article was titled “…
Radicava (edaravone), the first approved treatment for amyotrophic lateral sclerosis in 22 years, is being welcomed with “a great deal of excitement” in the ALS community, an ALS Association executive said. The excitement stems both from Radicava’s potential to treat the disease and the hope that its approval will lead…
Below is a transcript of the ALS News Today interview with Calaneet Balas, executive vice president of strategy for the ALS Association. The nonprofit association, established in 1985, is active in promoting research into ALS, providing assistance to patients through its network of 39 state chapters, and in coordinating care though its…
Edaravone — now more widely known by its U.S. brand name, Radicava — has produced “a minor miracle” for some amyotrophic lateral sclerosis patients, said Stephen Byer, co-director of ALS Worldwide. “We have found and continue to find great benefit in terms of slowing, stopping and, in some…
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects motor neurons, or nerve cells that control muscle movement, causing their death. Rilutek (riluzole), Tiglutik (riluzole oral suspension), and Radicava (edaravone) are the only medications currently approved to treat…
Harvard Medical School researchers have discovered how a mutation of the C9ORF72 gene causes the changes in energy production and nerve cell function that are linked to inherited forms of ALS and frontotemporal dementia, or FTD. The mutation produces two toxic proteins that can disrupt the normal processing of genetic instructions,…
Measuring neurofilaments in brain and spinal fluid appears to be a reliable way of confirming an ALS diagnosis, Belgian and German researchers report. This finding is important because it takes an average of a year from the appearance of the first symptoms before doctors can diagnose the disease. The discovery could…
